Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
| ▸ | SCD | O00767 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6467973 | 1.00 | SIGMAR1 (0.45) | SIGMAR1TRPM8DRD2HTR2AEPHX2 | |
| SCHEMBL4152628 | 0.80 | SIGMAR1 (0.43) | SIGMAR1TRPM8DRD2HTR2AEPHX2 | |
| SCHEMBL27700168 | 0.80 | SIGMAR1 (0.43) | SIGMAR1TRPM8DRD2HTR2AEPHX2 | |
| SCHEMBL7103909 | 0.80 | SIGMAR1 (0.43) | SIGMAR1TRPM8DRD2HTR2AEPHX2 | |
| SCHEMBL31620031 | 0.80 | SIGMAR1 (0.43) | SIGMAR1TRPM8DRD2HTR2AEPHX2 | |
| SCHEMBL27969301 | 0.80 | SIGMAR1 (0.43) | SIGMAR1TRPM8DRD2HTR2AEPHX2 | |
| SCHEMBL7394070 | 0.80 | SIGMAR1 (0.43) | SIGMAR1TRPM8DRD2HTR2AEPHX2 | |
| SCHEMBL3926924 | 0.78 | SIGMAR1 (0.47) | SIGMAR1TRPM8DRD2HTR2AEPHX2 | |
| SCHEMBL11884586 | 0.77 | SIGMAR1 (0.41) | SIGMAR1TRPM8DRD2HTR2AEPHX2 | |
| SCHEMBL1246125 | 0.77 | SIGMAR1 (0.44) | SIGMAR1TRPM8DRD2HTR2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12466802-B2 | Nebivolol synthesis method and intermediate compound thereof | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2025-11-11 | — | — | US | disclosed |
| EP-3974419-A2 | NEBIVOLOL SYNTHESIS METHOD AND INTERMEDIATE COMPOUND THEREOF | Zhejiang Ausun Pharmaceutical Co., Ltd. (CN) | 2022-03-30 | — | — | EP | disclosed |
| US-20220056003-A1 | NEBIVOLOL SYNTHESIS METHOD AND INTERMEDIATE COMPOUND THEREOF | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2022-02-24 | — | — | US | disclosed |
| EP-3299364-B1 | NEBIVOLOL SYNTHESIS METHOD AND INTERMEDIATE COMPOUND THEREOF | ZHEJIANG AUSUN PHARMACEUTICAL CO LTD (CN) | 2021-10-20 | — | — | EP | disclosed |
| US-11142512-B2 | Nebivolol synthesis method and intermediate compound thereof | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2021-10-12 | — | — | US | disclosed |
| EP-3165925-B1 | METHODS FOR THE DIAGNOSIS OF COLORECTAL CANCER | MED LIFE DISCOVERIES LP (CA) | 2021-09-08 | — | — | EP | disclosed |
| US-20210041444-A1 | METHODS FOR DIAGNOSING A COLORECTAL CANCER (CRC) HEALTH STATE OR CHANGE IN CRC HEALTH STATE, OR FOR DIAGNOSING RISK OF DEVELOPING CRC OR THE PRESENCE OF CRC IN A SUBJECT | PHENOMENOME DISCOVERIES INC. (CA) | 2021-02-11 | — | — | US | disclosed |
| US-10697969-B2 | Methods for diagnosing a colorectal cancer (CRC) health state or change in CRC health state, or for diagnosing risk of developing CRC or the presence of CRC in a subject | MED-LIFE DISCOVERIES LP (CA) | 2020-06-30 | — | — | US | disclosed |
| US-20200102282-A1 | NEBIVOLOL SYNTHESIS METHOD AND INTERMEDIATE COMPOUND THEREOF | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2020-04-02 | — | — | US | disclosed |
| US-20180141926-A1 | NEBIVOLOL SYNTHESIS METHOD AND INTERMEDIATE COMPOUND THEREOF | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2018-05-24 | — | — | US | disclosed |
| WO-2012033668-A1 | HYDROXYCHROMAN DERIVATIVES AS ENGINE OIL ANTIOXIDANTS | THE LUBRIZOL CORPORATION (US) | 2012-03-15 | — | — | WO | disclosed |
| US-20080255764-A1 | Methods for the Diagnosis of Colorectal Cancer and Ovarian Cancer by the Measurement of Vitamin E-Related Metabolites | PHENOMENOME DISCOVERIES INC. (CA) | 2008-10-16 | — | — | US | disclosed |
| EP-1931995-A2 | METHODS FOR THE DIAGNOSIS OF COLORECTAL CANCER AND OVARIAN CANCER HEALTH STATES | Phenomenome Discoveries Inc. (CA) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007030928-A2 | METHOD FOR THE DIAGNOSIS OF COLORECTAL CANCER AND OVARIAN CANCER BY THE MEASUREMENT OF VITAMIN E-RELATED METABOLITES | PHENOMENOME DISCOVERIES INC. (CA) | 2007-03-22 | — | — | WO | disclosed |
| US-7038067-B2 | Process for synthesizing d-tocotrienols from 2-vinylchromane compound | YASOO HEALTH, INC. (US) | 2006-05-02 | — | — | US | disclosed |
| US-20050124688-A1 | Process for synthesizing d-tocotrienols from 2-vinylchromane compound | YASOO HEALTH, INC. | 2005-06-09 | — | — | US | disclosed |
| US-20050124687-A1 | Process for synthesizing d-tocotrienols | COULADOUROS ELIAS A (GR) | 2005-06-09 | — | — | US | disclosed |
| WO-2005035491-A2 | PROCESS FOR SYNTHESIZING d-TOCOTRIENOLS FROM 2- VINYLCHROMANE COMPOUND | YASOO HEALTH, INC. (US) | 2005-04-21 | — | — | WO | disclosed |
| WO-2005035490-A2 | PROCESS FOR SYNTHESIZING d-TOCOTRIENOLS | YASOO HEALTH, INC. (US) | 2005-04-21 | — | — | WO | disclosed |
| WO-1991012253-A1 | TETRALIN AND CHROMAN DERIVATIVES USEFUL IN THE TREATMENT OF ASTHMA, ARTHRITIS, AND RELATED DISEASES | PFIZER INC. (US) | 1991-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12466802-B2 | Nebivolol synthesis method and intermediate compound thereof | CYP4A11, CYP11B2, CYP11B1 | SIGMAR1 1746/4885TRPM8 2697/4885DRD2 222/4885 |
| US-20200102282-A1 | NEBIVOLOL SYNTHESIS METHOD AND INTERMEDIATE COMPOUND THEREOF | CYP4A11, CYP11B2, ADRB1 | SIGMAR1 1730/4885TRPM8 2817/4885DRD2 205/4885 |
| US-20050124688-A1 | Process for synthesizing d-tocotrienols from 2-vinylchromane compound | FDFT1, DHCR7, DDT | SIGMAR1 4602/4885TRPM8 3252/4885DRD2 231/4885 |
| US-20050124687-A1 | Process for synthesizing d-tocotrienols | UGT8, DDOST, GGPS1 | SIGMAR1 4450/4885TRPM8 3294/4885DRD2 2173/4885 |
| US-11142512-B2 | Nebivolol synthesis method and intermediate compound thereof | CYP4A11, CYP11B2, ADRB1 | SIGMAR1 1730/4885TRPM8 2817/4885DRD2 205/4885 |
| US-20220056003-A1 | NEBIVOLOL SYNTHESIS METHOD AND INTERMEDIATE COMPOUND THEREOF | CYP4A11, CYP11B2, CYP11B1 | SIGMAR1 1746/4885TRPM8 2697/4885DRD2 222/4885 |
| US-20180141926-A1 | NEBIVOLOL SYNTHESIS METHOD AND INTERMEDIATE COMPOUND THEREOF | CYP4A11, CYP11B2, ADRB1 | SIGMAR1 1730/4885TRPM8 2817/4885DRD2 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.